MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans

MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans
复制标题

DOI:
10.1002/eji.200425799
复制
发表时间:
2005-03-01
影响因子:
5.4
通讯作者:
Mancuso, G
Mancuso, G
中科院分区:
医学3区
文献类型:
--
作者:
Biondo, C;Midiri, A;Mancuso, G

文献摘要

被引文献

相似文献

我们研究了Toll样受体(TLR)和衔接蛋白MyD 88在新生隐球菌(一种致病性包囊酵母)先天免疫应答中的潜在作用。与野生型对照组相比,MyD 88(-/-)或TLR 2(-/-)小鼠的腹膜巨噬细胞在体外用全酵母刺激后释放的TNF-α显著减少。相比之下,相对于C3 H/HeN对照,在来自C3 H/HeJ小鼠的巨噬细胞之间没有注意到TNF-α释放的差异,所述C3 H/HeJ小鼠在TLR 4中具有功能缺失突变。当MyD 88或TLR 2缺陷小鼠感染低剂量的H99血清型A菌株时,所有对照动物,但MyD 88(-/-)动物无一存活,仅38%的TLR 2(-/-)动物存活,这与突变小鼠中较高的真菌负荷有关。MyD 88(-/-)和TLR 2(-/-)动物在感染期间在各种器官中均显示TNF-α、IL-12 p40和/或IFN-γ表达降低。C3 H/HeJ小鼠和C3 H/HeN对照小鼠对实验性隐球菌病的易感性无差异。总之,我们的数据表明,TLR 2和MyD 88,而不是TLR 4,通过诱导增加TNF-α,IL-12和IFN-γ的表达,对抗隐球菌防御起关键作用。
We investigated here the potential role of Toll-like receptors (TLR) and the adaptor protein MyD88 in innate immunity responses to Cryptococcus neoformans, a pathogenic encapsulated yeast. Peritoneal macrophages from MyD88(-/-) or TLR2(-/-) mice released significantly less TNF-alpha, compared with wild-type controls, after in vitro stimulation with whole yeasts. In contrast, no differences in TNF-alpha release were noted between macrophages from C3H/HeJ mice, which have a loss of function mutation in TLR4, relative to C3H/HeN controls. When MyD88- or TLR2-deficient mice were infected with low doses of the H99 serotype A strain, all of the control animals, but none of MyD88(-/-) and only 38% of the TLR2(-/-) animals survived, in association with higher fungal burden in the mutant mice. Both MyD88(-/-) and TLR2(-/-) animals showed decreased TNF-alpha, IL-12p40 and/or IFN-gamma expression in various organs during infection. No difference in susceptibility to experimental cryptococcosis was found between C3H/HeJ mice and C3H/HeN controls. In conclusion, our data indicate that TLR2 and MyD88, but not TLR4, critically contribute to anti-cryptococcal defenses through the induction of increased TNF-alpha, IL-12 and IFN-gamma expression.